Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the current ...

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Right now, that's none other than Eli Lilly (NYSE: LLY). However, others are looking to challenge its dominance. Recent ...

Insulin costs have declined over the past two years, and additional price cuts are expected in 2026. Medicare will lower prices for several diabetes drugs, including Januvia and Jardiance. Federal and ...

Lilly will also gain certain rights to MeiraGTx’s proprietary riboswitch technology for use in gene editing in the eye. Under ...

During a meeting this week, an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed 10 new ...

The announcement comes on the heels of a deal with the Trump administration to expand access to weight-loss drugs and reduce ...

Eli Lilly's Mounjaro became India's highest-selling drug in October with ₹100 crore sales. The anti-obesity treatment now ...

Eli Lilly and Co.’s stock hit an all-time high and almost reached $1,000 per share on Tuesday in the wake of several ...